Glyscend is developing novel non-absorbable polymers that are orally-delivered for the treatment of Type 2 Diabetes.
Glyscend is developing novel non-absorbable polymers that are orally-delivered for the treatment of Type 2 Diabetes. Glyscend’s polymer technology platform evolved from research at Johns Hopkins University, where scientists, in collaboration with clinicians at the Royal Adelaide Hospital were evaluating the mechanisms that result in significantly improved glucose and metabolic regulation following certain types of bariatric surgery. They discovered that specifically designed polymers, delivered orally, could mimic this post-surgical effect, creating a new class of therapies for Type 2 Diabetes and potentially other metabolic disorders.
